A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Status:
Completed
Trial end date:
2019-09-06
Target enrollment:
Participant gender:
Summary
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits,
hands, and feet) affects approximately 4.8% of the US population and is believed to be caused
by an overactive cholinergic response of the sweat glands. Sofpironium bromide (BBI-4000) is
a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 2
study will assess the long-term safety, tolerability, pharmacokinetics and efficacy of
sofpironium bromide gel applied topically to pediatric subjects with axillary hyperhidrosis.